Effect of Dapagliflozin on Elderly Patients with Heart Failure with Preserved Ejection Fraction Combined with Type 2 Diabetes Mellitus
Objective:To investigate the effect of Dapagliflozin on elderly patients with heart failure with preserved ejection fraction(HFpEF)combined with type 2 diabetes mellitus.Method:A total of 80 elderly patients with HFpEF combined with type 2 diabetes admitted to Enshi Central Hospital from June to December 2021 were selected.They were divided into control group(n=40)and experimental group(n=40)according to random number table method.The control group received conventional treatment,and the experimental group received Dapagliflozin on the basis of the control group.Cardiac function indexes,inflammatory factors before and after 1 year of treatment,major cardiovascular adverse events and complications were compared between the two groups.Result:After 1 year of treatment,the levels of N-terminal pro-B-type natriuretic peptide(NT-proBNP)and angiotensin Ⅱ(AngⅡ)in both groups were lower than those before treatment,the left ventricular ejection fraction was higher than that before treatment;the levels of NT-proBNP and AngⅡin the experimental group were lower than those in the control group,and left ventricular ejection fraction was higher than that in control group,the differences were statistically significant(P<0.05).After 1 year of treatment,the levels of C-reactive protein,tumor necrosis factor-α and the ratio of monocyte/high-density lipoprotein cholesterol in the two groups were lower than those before treatment,and the levels of C-reactive protein,tumor necrosis factor-α and the ratio of monocyte/high-density lipoprotein cholesterol in the experimental group were lower than those in the control group,the differences were statistically significant(P<0.05).The incidence of major adverse cardiovascular events in the experimental group was lower than that in control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of complications between the two groups(P>0.05).Conclusion:Dapagliflozin can enhance the cardiac function of elderly HFpEF patients combined with type 2 diabetes,reduce the levels of NT-proBNP,AngⅡ and inflammatory factors,and reduce the occurrence of major cardiovascular adverse events.
DapagliflozinHeart failure with preserved ejection fractionType 2 diabetesNT-proBNPAng Ⅱ
万方数据
维普
